Drug intelligence / Profile preview

PIN-2

Development stage: Preclinical
Lead developer: PIN Pharma
Modality: Peptides
Administration: Intravenous

Overview

PIN-2 is a novel immunomodulatory peptide that acts as a precision immune stimulant. It links the innate and adaptive immune systems to enhance the body's ability to fight cancer. In preclinical studies, PIN-2 impacted tumor progression, increased survival (in combination with cyclophosphamide), overrode tumor-mediated immune resistance, and reduced distant site metastasis (in combination with a checkpoint inhibitor). A first-in-human clinical trial in patients with advanced solid tumors demonstrated pharmacologic activity and safety, showing a rapid onset of action with a marked increase in circulating TNF-α.

Other names: Precision Immune Stimulant

Targets

IFNG (Interferon gamma)IL12 (Interleukin-12)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on PIN-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PIN-2.

Explore the full profile